Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer

Open access

Abstract

Abstract Combinatorial clinical trials of PARP inhibitors with immunotherapies are ongoing, yet the immunomodulatory effects of PARP inhibition have been incompletely studied. Here, we sought to dissect the mechanisms underlying PARP inhibitor–induced changes in the tumor microenvironment of BRCA1-deficient triple-negative breast cancer (TNBC). We demonstrate that the PARP inhibitor olaparib induces CD8+ T-cell infiltration and activation in vivo, and that CD8+ T-cell depletion severely compromises antitumor efficacy. Olaparib-induced T-cell recruitment is mediated through activation of the cGAS/STING pathway in tumor cells with paracrine activation of dendritic cells and is more pronounced in HR-deficient compared with HR-proficient TNBC cells and in vivo models. CRISPR-mediated knockout of STING in cancer cells prevents proinflammatory signaling and is sufficient to abolish olaparib-induced T-cell infiltration in vivo. These findings elucidate an additional mechanism of action of PARP inhibitors and provide a rationale for combining PARP inhibition with immunotherapies for the treatment of TNBC. Significance: This work demonstrates cross-talk between PARP inhibition and the tumor microenvironment related to STING/TBK1/IRF3 pathway activation in cancer cells that governs CD8+ T-cell recruitment and antitumor efficacy. The data provide insight into the mechanism of action of PARP inhibitors in BRCA-associated breast cancer. This article is highlighted in the In This Issue feature, p. 681

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-18-1218

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Research works printed but not linked: 1

  1. Ferreira, 2010., ImageJ user guide-IJ 1.46

Cited by

See all 743

Metadata

Authors
Pantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A. K., Kothari, A., Wang, D., Visal, T., Li, M. K., Pinto, J., Castrillon, J. A., Cheney, E. M., Bouwman, P., Jonkers, J., Rottenberg, S., Guerriero, J. L., Wulf, G. M., & Shapiro, G. I.
Affiliations
  • Harvard University (US)
  • Beth Israel Deaconess Medical Center (US)
  • 2Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
  • Dana-Farber Cancer Institute (US)
  • 4Breast Tumor Immunology Laboratory, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • The Netherlands Cancer Institute (NL)
  • University of Bern (CH)
  • Brigham and Women's Hospital (US)
Corresponding author
Shapiro, Geoffrey I.
Venue
Cancer Discovery
Published
2019-06-01
Volume
9
Issue
6
Pages
722-737
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2942052760
Cited by
743
References
44
Citations by year
2026: 106 · 2025: 83 · 2024: 110 · 2023: 112 · 2022: 119 · 2021: 120 · 2020: 73 · 2019: 20
FWCI
34.74
Type
journal article
Language
en
Open access
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Bern Open Repository and Information System (University of Bern) (submittedVersion, other-oa)
  • Open Access CRIS of the University of Bern
Funders
  • HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI) (P50 CA168504, R01 CA090687, R01 CA226776)
  • Susan G. Komen for the CureSusan G. Komen for the Cure (Susan G. Komen) (CCR18547597)
  • EC | European Research CouncilEC | European Research Council (ERC) (CoG-681572)
Topics
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords
PARP inhibitors, olaparib, triple-negative breast cancer, BRCA1 deficiency, CD8+ T cell recruitment, cGAS-STING pathway, tumor microenvironment, dendritic cells, combination immunotherapy, antitumor immunity
MeSH terms
Poly(ADP-ribose) Polymerase Inhibitors, STING Protein, Female, Humans, Immunohistochemistry, Membrane Proteins, Signal Transduction, Biomarkers, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, BRCA1 Protein, BRCA2 Protein, Tumor Microenvironment, Triple Negative Breast Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-18-1218
The paper
Pantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A. K., Kothari, A., Wang, D., Visal, T., Li, M. K., Pinto, J., Castrillon, J. A., Cheney, E. M., Bouwman, P., Jonkers, J., Rottenberg, S., Guerriero, J. L., Wulf, G. M., & Shapiro, G. I. (2019). PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-18-1218

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.